Pre-Op THP Shows 64% pCR in Early HER2+ Breast Cancer ECOG-ACRIN Cancer Research Group
At #ASCO2025: 64% of early-stage HER2+, ER- breast cancer patients had a pCR with 12 weeks of THP. The CompassHER2 trial could change the chemo standard.#BreastCancer #OncoTwitter #ECOGACRIN #ClinicalResearch| ECOG-ACRIN Cancer Research Group
